Provided by Tiger Trade Technology Pte. Ltd.

Titan America

15.57
-0.2500-1.58%
Post-market: 15.570.00000.00%17:01 EST
Volume:248.21K
Turnover:3.87M
Market Cap:2.87B
PE:15.80
High:15.90
Open:15.90
Low:15.46
Close:15.82
52wk High:17.78
52wk Low:10.80
Shares:184.36M
Float Shares:24.00M
Volume Ratio:0.67
T/O Rate:1.03%
Dividend:0.12
Dividend Rate:0.77%
EPS(TTM):0.9854
EPS(LYR):0.9470
ROE:20.31%
ROA:9.50%
PB:2.89
PE(LYR):16.44

Loading ...

Titan America (TTAM): Assessing Valuation Following Recent Pullback in Share Price

Simply Wall St.
·
Nov 15

Titan America SA’s Earnings Call: Strong Growth Amid Challenges

TIPRANKS
·
Nov 07

Titan America Reports Strong Q3 2025 Results with Revised Revenue Outlook

TIPRANKS
·
Nov 06

Titan America SA Reports Q3 Revenue of $436.8 Million and Net Income of $57.4 Million

Reuters
·
Nov 06

Titan America SA to Release Q3 2025 Financial Results

Reuters
·
Oct 23

Titan America Gets Key Miami-Dade Approvals for Lintel Products

MT Newswires Live
·
Oct 09

Titan America SA Announces Leadership Change

TIPRANKS
·
Sep 19

Titan America SA to Participate in Jefferies 2025 Industrials Conference in New York City

Reuters
·
Sep 03

Titan America SA Declares $0.04 Per Share Distribution for Q3 2025

Reuters
·
Jul 30

Titan America Q2 EPS $0.28 Misses $0.31 Estimate, Sales $429.200M Miss $440.054M Estimate

Benzinga
·
Jul 30

Titan America Shares Fall After Downgrade From Stifel

MT Newswires Live
·
Jul 29

Stifel Downgrades to Hold From Buy, Adjusts Price Target to $15 From $17

MT Newswires Live
·
Jul 28

Titan America Sa : Stifel Cuts to Hold From Buy; Cuts Target Price to $15 From $17

THOMSON REUTERS
·
Jul 28

Titan America Shares Fall After BofA Securities Downgrade

MT Newswires Live
·
Jul 25

Titan America Sa : Bofa Global Research Cuts to Underperform From Neutral

THOMSON REUTERS
·
Jul 24

BofA Securities Downgrades Titan America to Underperform From Neutral

MT Newswires Live
·
Jul 24

Titan America Cut to Underperform From Neutral by B of A Securities

Dow Jones
·
Jul 24

Press Release: TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets

Dow Jones
·
Jul 14

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million

MT Newswires Live
·
Jun 16

Press Release: 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dow Jones
·
Jun 14